Drugs & Therapy Perspectives

, Volume 14, Issue 1, pp 14–16 | Cite as

Investment in effective migraine therapy could reduce the overall costs of the disorder

Drugs Economics and Quality of Life


Migraine Adis International Limited Risperidone Indirect Cost National Health Service 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Coukell AJ, Lamb HM. Sumatriptan: a pharmacoeconomic review of its use in migraine. Pharmacoeconomics 1997 May; 11(5): 473–90PubMedCrossRefGoogle Scholar
  2. 2.
    Ferrari MD. The economic burden of migraine to society. Pharmacoeconomics 1998 Jun; 13(6): 667–76PubMedCrossRefGoogle Scholar
  3. 3.
    Parry TG. The prevalence and costs of migraine in Australia. Kensington: University of New South Wales, 1992. Centre for Applied Economic Research (CAER) working paper no.: 1992/1Google Scholar
  4. 4.
    O’Brien B, Goeree R, Streiner D. Prevalence of migraine headache in Canada: a population-based survey. Int J Epidemiol 1994; 23: 1020–6PubMedCrossRefGoogle Scholar
  5. 5.
    van Roijen L, Essink-Bot M-L, Koopmanschap MA, et al. Societal perspective on the burden of migraine in The Netherlands. Pharmacoeconomics 1995; 7(2): 170–9PubMedCrossRefGoogle Scholar
  6. 6.
    Láinez JM, Titus F, Cobaleda S, et al. Socioeconomic impact of migraine [abstract]. Funct Neurol 1996; 11: 133Google Scholar
  7. 7.
    Björk S, Roos P. Economic aspects of migraine in Sweden. Lund: Institute for Health Economics, 1991. Working paper no.: 8Google Scholar
  8. 8.
    Blau JN, Drummond MR Migraine. Office of Health Economics (OHE). London: OHE, 1991Google Scholar
  9. 9.
    Cull RE, Wells NEJ, Miocevich ML. The economic cost of migraine. Br J Med Econ 1992; 2: 103–15Google Scholar
  10. 10.
    Osterhaus JT, Gutterman DL, Plachetka JR. Healthcare resource and lost labour costs of migraine headache in the US. Pharmacoeconomics 1992; 2(1): 67–76PubMedCrossRefGoogle Scholar
  11. 11.
    Streator SE, Shearer SW. Pharmacoeconomic impact of injectable sumatriptan on migraine-associated healthcare costs. Am J Manage Care 1996; 2: 139–43Google Scholar
  12. 12.
    Stang PE, Osterhaus JT. Impact of migraine in the United States: data from the National Health Interview Survey. Headache 1993; 33: 29–35PubMedCrossRefGoogle Scholar
  13. 13.
    Bloomberg Financial Markets. Electronic database. New York: LP Bloomberg, 1998Google Scholar
  14. 14.
    International Monetary Fund (IMF). International financial statistics. Vol. 11 (1). Washington, DC: IMF, 1998Google Scholar
  15. 15.
    Tailor drug choice to headache severity in acute migraine attacks. Drug Ther Perspect 1999 May 24; 13(10): 8–11Google Scholar
  16. 16.
    Alot of ammunition but does migraine prophylaxis hit the target? Drug Ther Perspect 1999 Jun 7; 13(11): 5–8Google Scholar
  17. 17.
    Solomon GD, Price KL. Burden of migraine: a review of its socioeconomic impact. Pharmacoeconomics 1997; 11 Suppl. 1: 1–10PubMedCrossRefGoogle Scholar
  18. 18.
    Welch KMA. Drug therapy of migraine. N Engl J Med 1993 Nov 11; 329: 1476–83PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 1999

Personalised recommendations